GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Ending Cash Position

Larimar Therapeutics (STU:ZA71) Ending Cash Position : €32.80 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Ending Cash Position?

Larimar Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 was €32.80 Mil.

Larimar Therapeutics's quarterly Ending Cash Position declined from Mar. 2024 (€102.55 Mil) to Jun. 2024 (€31.26 Mil) but then increased from Jun. 2024 (€31.26 Mil) to Sep. 2024 (€32.80 Mil).

Larimar Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€63.22 Mil) to Dec. 2022 (€26.59 Mil) and declined from Dec. 2022 (€26.59 Mil) to Dec. 2023 (€25.76 Mil).

Larimar Therapeutics Ending Cash Position Historical Data

The historical data trend for Larimar Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Ending Cash Position Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
0.91 57.12 63.22 26.59 25.76

Larimar Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.54 25.76 102.55 31.26 32.80

Larimar Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Larimar Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=25.826+-0.068999999999999
=25.76

Larimar Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=30.319+2.483
=32.80

Larimar Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Ending Cash Position
Comparable Companies
ALT ADAP ABOS GALT RVPH LBPH PDSB ATRA PRAX INMB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
LRMR:USA
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Website
https://www.larimartx.com
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines